Amundi Buys 19,925 Shares of Embecta Corp. (NASDAQ:EMBC)

Amundi boosted its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 161.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,287 shares of the company's stock after purchasing an additional 19,925 shares during the quarter. Amundi owned approximately 0.06% of Embecta worth $655,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Garden State Investment Advisory Services LLC bought a new position in Embecta in the third quarter worth $438,000. Barclays PLC grew its stake in shares of Embecta by 41.1% in the third quarter. Barclays PLC now owns 97,930 shares of the company's stock worth $1,381,000 after acquiring an additional 28,523 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Embecta in the third quarter worth $594,000. Jane Street Group LLC grew its stake in shares of Embecta by 156.1% in the third quarter. Jane Street Group LLC now owns 176,487 shares of the company's stock worth $2,488,000 after acquiring an additional 107,567 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Embecta by 3.4% in the third quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company's stock worth $19,564,000 after acquiring an additional 45,228 shares during the last quarter. Institutional investors own 93.83% of the company's stock.

Analyst Ratings Changes

EMBC has been the topic of a number of recent research reports. BTIG Research raised Embecta from a "neutral" rating to a "buy" rating and set a $26.00 target price on the stock in a research note on Wednesday, November 27th. Morgan Stanley raised Embecta from an "underweight" rating to an "equal weight" rating and increased their target price for the stock from $13.00 to $20.00 in a research note on Monday, December 2nd.

Remove Ads

Embecta Price Performance

Shares of Embecta stock traded down $0.41 during trading on Friday, hitting $12.82. 1,305,567 shares of the company's stock traded hands, compared to its average volume of 421,952. Embecta Corp. has a 1 year low of $9.93 and a 1 year high of $21.48. The stock has a market capitalization of $745.28 million, a P/E ratio of 12.82, a PEG ratio of 0.78 and a beta of 1.27. The business has a 50-day simple moving average of $15.94 and a 200-day simple moving average of $16.37.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. On average, equities analysts predict that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were given a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.60 annualized dividend and a dividend yield of 4.68%. Embecta's dividend payout ratio (DPR) is presently 60.00%.

Insider Activity at Embecta

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the transaction, the director now directly owns 36,133 shares of the company's stock, valued at approximately $591,858.54. This trade represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.42% of the stock is currently owned by insiders.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.